Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors. 31707682 2020
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Here, we provide our perspective on how to improve the success of CAR T therapy in solid tumors by focusing on the aspects of target selection and the related TME in CAR T cell design, especially stressing the interplay between them. 30906625 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 GeneticVariation phenotype BEFREE These works confirmed that simultaneous use of cytokines, for example, rhIL-12, can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors. 31237116 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Although CAR-T cell therapy did not have satisfactory responses in solid tumors, researchers were still holding an optimistic attitude towards its future efficacy with more modifications of its structure. 30886654 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE The data confirmed the antitumor ability and safety of CAR-T cells targeting EpCAM and may provide a new target for CAR-T cell therapies in treating solid tumors. 30693795 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 GeneticVariation phenotype BEFREE Our results guide new therapeutic options for GD2.CAR-Ts in patients with neuroblastoma, and CAR-T development for a broad range of solid tumors. 30617136 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE However, due to the lack of ideal tumor surface antigens, CAR-T cell therapy has limited success in treating solid tumors. 31597088 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 AlteredExpression phenotype BEFREE Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. 30678555 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors. 30636882 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE The tumor vasculature an attractive CAR T cell target in solid tumors. 31628559 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE There are obvious differences between the two countries in CAR-targeted antigens in solid tumors and genetic modifications besides CARs for enhancing the potency of CAR T-cells. 30307029 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Amph-Ligand Vaccine Enhances CAR-T Cell Activity against Solid Tumors. 31324609 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Innovative approaches such as haploidentical stem cell transplantation, new monoclonal antibodies and immunotherapies as well as Chimeric Antigen Receptor T-cell (CAR-T cell) therapies are on the way as promising treatment options especially for patients with refractory hematologic malignancies and even in solid tumors. 29556955 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 AlteredExpression phenotype BEFREE Many potential targets for CAR-T cells in solid tumors are expressed in some normal tissues, raising concern for off-tumor toxicity. 30889382 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. 31754328 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE The anti-VEGFR2 CAR but not mock T cells mediated specific lysis of 293-KDR cells expressing human VEGFR2 and might be considered as a candidate for adoptive T-cell immunotherapy of solid tumors. 30724452 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE CD56-CAR-T cell therapy is a safe and effective approach and may be an option for children with solid tumors who are nonresponsive to conventional radiotherapy and chemotherapy, or are unsuitable for hematopoietic stem cell transplantation. 31651858 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Due to their high heterogeneity and complex tumor microenvironment, the treatment of solid tumors by CAR-T cell technology is limited. 31497363 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 AlteredExpression phenotype BEFREE TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. 31161552 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 GeneticVariation phenotype BEFREE CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. 30999624 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Application of CAR T cells for the treatment of solid tumors. 31383408 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Although CAR T cell therapy mediates robust responses in patients with hematological malignancies, this approach has been less effective for treating patients with solid tumors. 30842774 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE However, CAR-T cell therapy has shown limited efficacy for the treatment of solid tumors. 31142602 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Effective deployment of CAR T-cell immunotherapy for solid tumors has proven challenging to date, due to a series of formidable hurdles. 31038366 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm
0.100 Biomarker phenotype BEFREE Here we demonstrate an approach to enhancing CAR-T function in solid tumors by directly vaccine-boosting donor cells through their chimeric receptor in vivo. 31296767 2019